Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis Vaccines
New findings from Pasteur Institute in the area of tuberculosis vaccines described
December 31st, 2008
Research findings, 'Immunogenicity and protective efficacy of tuberculosis subunit vaccines expressing PPE44 (Rv2770c),' are discussed in a new report. "In this study we have evaluated the vaccine potential of a Mycobacterium tuberculosis antigen of the PPE protein family, namely PPE44 (Rv2770c). PPE44-specific immune responses could be detected in mice acutely, chronically and latently infected with M. tuberculosis," investigators in Brussels, Belgium report. "Vaccination of mice with a plasmid DNA vaccine coding for PPE44 or recombinant PPE44 protein formulated in adjuvant generated strong cellular and humoral immune responses; immunodominant T cell...
Source: Vaccine Weekly (2008-12-31)
|
